Ritonavir & Lopinavir bulk supplier for pharma manufacturers

Ritonavir & Lopinavir Suppliers & Bulk Manufacturers

Available Forms: Tablet and Oral Solution

Available Strengths: Tab: Lopinavir 200 mg + Ritonavir 50 mg; oral solution:80 mg / 20 mg per mL

Reference Brands: Kaletra(US & EU)

Lopinavir & Ritonavir Tablets (Kaletra®) combine two protease inhibitors for HIV treatment. Available in 200/50 mg strength, they are sourced via PharmaTradz from WHO-GMP-approved manufacturers. Perfect for bulk procurement, tenders, and public health programs ensuring global access to essential HIV medicines.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ritonavir & Lopinavir? List it or send an offer →

Product Description:

Lopinavir & Ritonavir Tablets, widely marketed as Kaletra®, are a fixed-dose combination of two protease inhibitors used in the treatment of HIV-1 infection. Each tablet typically contains Lopinavir 200 mg and Ritonavir 50 mg, with Ritonavir boosting the effectiveness of Lopinavir. This antiretroviral combination remains vital in HIV care, especially in resource-limited settings and global treatment programs. PharmaTradz connects global buyers, NGOs, and procurement agencies with WHO-GMP and USFDA-approved manufacturers offering bulk supply at competitive rates. Ideal for tenders and institutional supply, this therapy supports consistent, affordable access to HIV medications worldwide.

Ritonavir & Lopinavir — third party manufacturing & bulk supply

Ritonavir & Lopinavir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ritonavir & Lopinavir is supplied as Tablet and Oral Solution — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ritonavir & Lopinavir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ritonavir & Lopinavir →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ritonavir and Lopinavir are used together to treat HIV-1 infection. The combination helps reduce viral load, improve immune function, and slow the progression of HIV when used as part of antiretroviral therapy.

This combination is made from two antiretroviral agents: lopinavir, a protease inhibitor, and ritonavir, which enhances lopinavir levels by inhibiting its metabolism.

The common trade name is Kaletra.

Kaletra is manufactured by AbbVie (previously Abbott Laboratories).

The generic name is lopinavir and ritonavir.

The main brand name is Kaletra. Some regions also market it as Aluvia.

It is manufactured in various AbbVie/Abbott approved facilities, commonly in the USA, Europe, and India depending on the market and regulatory approval.